C12N 2795/10271
Demonstrated in vivo effect
C12N2795/10271 (Demonstrated in vivo effect) appears on 14 US grants and 17 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 17
- Assignees
- 10
- Inventors
- 27
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 1 | 0 |
| 2019 | 1 | 3 |
| 2020 | 0 | 1 |
| 2021 | 1 | 3 |
| 2022 | 3 | 0 |
| 2023 | 1 | 1 |
| 2024 | 2 | 5 |
| 2025 | 2 | 2 |
| 2026 | 3 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Bacteriophage, bacterial wilt disease control agent, and bacterial wilt disease control method14 Apr 2026US 12,599,142 B2Panefri Industrial Co., Ltd.
- Bacteriophage compositions for treating Pseudomonas infection7 Apr 2026US 12,594,312 B2Armata Pharmaceuticals, Inc.
- Bacteriophage compositions and methods for treatment of bacterial infections17 Mar 2026US 12,576,119 B2Baylor College of Medicine
- Antibacterial composition and uses thereof22 Apr 2025US 12,280,080 B2Erytech Pharma
- Bacteriophage compositions and methods for treatment of bacterial infections15 Apr 2025US 12,274,723 B2Baylor College of Medicine
- Bacteriophage compositions and methods for treatment of bacterial infections11 Sep 2025US 2025/0281555 A1Baylor College of Medicine
- Bacteriophage, bacterial wilt disease control agent, and bacterial wilt disease control method12 Jun 2025US 2025/0185668 A1Panefri Industrial Co., Ltd.
- Phage therapy of e coli infections7 Nov 2024US 2024/0366694 A1Erytech Pharma
- Bacteriophage compositions and methods for treatment of bacterial infections10 Oct 2024US 2024/0335489 A1Baylor College of Medicine
- Bacteriophage compositions for treating pseudomonas infection11 Jul 2024US 2024/0226205 A1Armata Pharmaceuticals, Inc.
Most cited
By later US patents
- Phage therapy of pseudomonas infections6US 10,077,431 B2Pherecydes Pharma · 2018
- Phage therapy of Pseudomonas infections3US 10,260,051 B2Pherecydes Pharma · 2019
- Phage therapy of E coli infections3US 10,918,680 B2Pherecydes Pharma · 2021
- Anti-bacterial compositions and uses thereof1US 11,690,885 B2Pherecydes Pharma · 2023